Preparation of HBV DNA reference standards and the experience of HBV NAT in Taiwan Dr. Hwei-Fang Cheng Department of Health, Taiwan.

Slides:

Advertisements

Similar presentations

High Throughput Donor Plasma NAT Screening Assay Applied to Acute HIV Detection in a Public Health Setting December 5, 2007 Josh Goldsmith, Ph.D. National.

Advertisements

Development of a Panel for Dengue Virus Maria Rios, PhD CBER/FDA Blood Products Advisory Committee Meeting December 14, 2010.

National Institute for Biological Standards and Control Assuring the quality of biological medicines Proposal for a Hepatitis A genotype panel Rob Anderson.

Jean-Michel PAWLOTSKY

HBsAg+ candidate blood donors HBV genotypes Number Origin(s) A1 43 S. Africa A2 72 Poland B 126 Hong Kong Malaysia Taiwan Thailand C 90 Hong Kong Malaysia.

Yi-Chen Yang, Drug Biology Division Bureau of Food and Drug Analysis Department of Health, Taiwan Collaborative study for establishment of the first national.

Paris, May 2004SoGAT XVII SoGAT and the Development of Standards Harvey Holmes Division of Retrovirology NIBSC, UK.

Karen Cristiano Biologicals Unit, CRIVIB Calibration against the WHO Standards of National Reference Preparations for detection of blood viruses by NAT:

Linearity Panels HIV RNA, HCV RNA, HBV DNA, and CMV DNA

XVIII SoGAT Washington 24 May 2005 SoGAT and HIV NAT Standards - 2 nd International Standard for HIV-1 RNA Harvey Holmes*, Clare Davis* and Alan Heath**

F. Kourgia, M. Vini, E. Zervou

COBAS TaqMan 48 Sales Brochure

Testing Source Plasma for Hepatitis B Virus by Nucleic Acid Testing Blood Products Advisory Committee Meeting Blood Products Advisory Committee Meeting.

R Diagnostics June 19, 2003 WNV FDA BPAC MeetingPCR NAT Blood Screening TaqScreen West Nile Virus Program - Roche Update James L. Gallarda, Ph.D. Roche.

PROFICIENCY TESTING OF IN-HOUSE NAT ASSAYS USED FOR BLOOD SCREENING XXI SoGAT International Working Group Meeting on the Standardization of NAT for the.

Generic Automated Sample Preparation for Commercial NAT Assays

ICBS Master Panels for Kit Evaluation: HCV, HBV, and HIV ( Howard A. Fields, Ph.D. Susan Diaz, MPH Division of Viral Hepatitis Centers.

Pooled Source Plasma NAT for HIV-1 An Update from the Bayer HIV-1 IND Study Barbara Masecar Bayer Corporation Raleigh, NC Blood Products Advisory Committee.

Faculty of Allied Medical Sciences Clinical Immunology & Serology Practice (MLIS 201)

BioLife Plasma Services Experience with HBV NAT Testing

HIV, HCV, and HBV NAT Controls Formulation, Stability and Performance Mark Manak BBI Diagnostics, Inc. A Division of SeraCare Life Sciences, Inc. SoGAT.

FDA’s Current Considerations of Parvovirus B19 Nucleic Acid Testing (NAT) Mei-ying W. Yu, PhD Division of Hematology CBER/FDA Extraordinary SoGAT Meeting.

DEVELOPMENT OF THE TOOLS FOR PCR-DETECTION OF HEPATITIS A AND C VIRUSES IN INTRAHOSPITAL VIRAL CONTAMINATION RESEARCH. 1 D. I. Ivanovsky Virology Institute,

Update on the Replacement of the HCV RNA International Standard Sally Baylis & Alan Heath, NIBSC SoGAT XX, Warsaw June 2007.

SOGAT Validation of HCV-RNA detection in small test pools on cadaveric samples Marco Koppelman #, Theo Cuypers #, Mirjam de Waal #, Maarten.

CE MARKING OF IVDDs - the NIBSC perspective Morag Ferguson Division of Virology.

Standardization – CBER update June 12, 2007 XX SoGAT Indira Hewlett, Ph.D. Chief, Lab. of Molecular Virology DETTD/CBER/FDA.

EQASs for Blood Borne Virus Genomes and BSE Prions from Cattle Brain and INSTAND Reference Materials H.-P. Grunert 1,2, K.-O. Habermehl 1,2, V. Lindig.

Establishment of the 1st WHO International Standard for Detection of Antibodies to Hepatitis B Virus Core Antigen (anti-HBc) SoGAT XXI 29 May 2009 Dr.

Standardisation of P. falciparum HBV, HCV and NAT Sally Baylis, NIBSC SoGAT XVIII.

Parvovirus B19 Genotype 2 Plasma, Sourced from the US Dr Sally A. Baylis, Division of Virology NIBSC.

Stability of HCV, HIV-1 and HBV nucleic acids in plasma samples stored at different temperatures Marta José, Rodrigo Gajardo and Juan I. Jorquera Instituto.

Yi-Chen Yang, Yu-Hsuan Chen, Show-Lan Chiu, Hwei-Fang Cheng Drug Biology Division, Bureau of Food and Drug Analysis Department of Health, Taiwan, ROC National.

Sensitivity of NAT blood screening assays in performance evaluation and proficiency programs Harry van Drimmelen, Nico Lelie, (VQC-Sanquin) and the principal.

NAT Detection of Blood Borne Viral Markers in Tissues from Cadaver Donors John Saldanha 1 and David Padley 2 1 Canadian Blood Services, Ottawa, Canada.

SoGAT XVII/Paris, 2004 Proficiency Testing of In-House Developed HIV-1 NAT for Blood Screening Michael Chudy, Paul-Ehrlich-Institut Division of Virology,

Monitoring the Performance of Nucleic Acid Tests using Data Generated from EDCNet and DigitalPT Wayne Dimech, Darren Jardine, Thu-Anh Pham and the staff.

1 Preparation of Standard Paneled Plasma for HBV, HCV, and HIV-1 in Japan Hisao Yugi Japanese Red Cross Central Blood Center Study Group of the Ministry.

SoGAT June 14, 2006 HCV-RNA and HIV-RNA detection in small test pools of cadaveric samples for viral safety of tissue transplants Maarten Koot#,

Development of Standard Reagents for WNV NAT M. Rios, A. Grinev, K. Sirnivasan, O. Wood, S. Daniel, I. Hewlett CBER/FDA.

Blood Products & related Biologicals: SoGAT, 28 May 09 1 |1 | Dr Ana Padilla, Blood Products & related Biologicals Essential Medicines and Pharmaceutical.

Update on the P. falciparum Standard & Replacement of the HBV & HCV International Standards Sally Baylis, NIBSC SoGAT XIX.

Controls for Blood Septicemia Nucleic Acid Tests Mark Manak BBI Diagnostics, Inc. A Division of SeraCare Life Sciences, Inc. SoGAT XIX Meeting Berne, Switzerland.

NUCLEIC ACID AMPLIFICATION TECHNOLOGY HCV-RNA / HBV-DNA / HIV-RNA testing blood and blood components for transfusion Italian External Quality Assessment.

Elisa Moretti Process and Analytical Development KEDRION S.p.A SoGAT XVI Paul Ehrlich Institut - Langen, Germany 3 rd July 2003 Automated Extraction for.

Serology - anti-HCV. anti-HIV, HBsAg NAT - HCV RNA - since 2000

An Overall View of Standardization May 26, 2004 Indira Hewlett, Ph.D. CBER/FDA.

DRK-Blutspendedienst West  nPrecipitation steps (PEG), centrifugation and careful resuspension of the invisible pelleted viral particles precede efficient.

DRK-BSD NSTOB & West 19th SoGAT Meeting, 14/15 June 2006, Bern Experience with Roche´s COBAS AmpliPrep/COBAS TaqMan96 automated PCR system in two large.

February 24, 2016 | 1 Paul Strengers MD, FFPM Sanquin Blood Supply Amsterdam The Netherlands Risk assessment schemes: Impact of.

CBER Update on status of West Nile virus test, lot release and validation panel development Indira Hewlett, Ph.D CBER/FDA Blood Products Advisory Committee.

SoGAT May 2005 Are conversion factors to international units assay related? Marco Koppelman, Henk Reesink, Nico Lelie, Theo Cuypers.

Informational Presentation: WHO Biological Standards Summary of January 29-30, 2007 WHO Meeting with WHO Collaborating Centres for Biological Standards.

HBV viral load 측정 및 임상적 의의 진단검사의학과이희주 Content v 임상적 의의 v 측정법.

Saeko Mizusawa, Yoshiaki Okada

Laboratory Diagnostics in Viral Hepatitis

Testing for Parvovirus B19 - Broadening the Assay to Cover Variants

Harvey Holmes, Clare Morris and Neil Berry Division of Retrovirology

Tom Øystein Jonassen, Mona Holberg-Petersen, Einar S. Berg

Performance Characteristics of a Quantitative Hepatitis C Virus RNA Assay Using COBAS AmpliPrep Total Nucleic Acid Isolation and COBAS TaqMan Hepatitis.

Update on CBER HIV-1 Subtype panel

Evaluation of Candidate Standard XX (97/650)

K.H. Buchheit, A. Daas, C.M. Nübling, J.M. Spieser 3 July 2003

Italian EQA study for HCV RNA, HIV RNA and HBV DNA G. M. Bisso, K

Viral Safety of Blood Products in Taiwan

1st International Standard for HIV-1 RNA NIBSC Code 97/656

Distributions of parvovirus B19 genotype 1-3 in blood donations

SoGAT meeting XXI May (2009), Brussels, Belgium

ANALYTICAL CONTROL SYSTEM AS A MEASURE TO ENSURE INFECTIOUS SAFETY OF HUMAN PLASMA FOR FRACTIONATION A.L. Poptsov FSBI “ROSPLASMA” RMSPC of FMBA of RUSSIA.

Presentation transcript:

Preparation of HBV DNA reference standards and the experience of HBV NAT in Taiwan Dr. Hwei-Fang Cheng Department of Health, Taiwan

HBV DNA Reference Standards  National HBV DNA standard ： 10 6 IU/mL, 0.5 mL/vial (relative to NIBSC HBV NAT standard)  National HBV DNA working reagent ： 10 3 IU/mL, 1 mL/vial (relative to NIBSC HBV NAT working reagent)  Intended use for HBV NAT testing of blood and pooled plasma and biological research

High titer (~10 9 IU/ml) HBV positive plasma (negative for anti-HIV,anti-HCV and NAT of HIV, HCV, HAV, and B19) a) genotype B b) virus inactivation: 60 o C for 1 hr c) dilute into ~10 6 IU/mL and ~10 3 IU/mL Diluents: pooled human plasma (negative for HBsAg, anti-HIV, anti-HCV and NAT of HIV, HCV, HBV, HAV, and B19)

Collaborative Study Participating Labs (11 Labs) US CBER/FDA National Institute of Infectious Diseases (NIID),Japan Canadian Blood Services National Institute for Biological Standards and Control (NIBSC) Victorian Infectious Diseases Reference Laboratory (VDRL), Australia NTUH Hepatitis Research Center, Taiwan Center of Disease Control, Taiwan BFDA, Taiwan Roche Diagnostics Artus GmbH Digene Diagnostic Technology

LabMethodology/kitResult (IU/ml) AIn-house real time PCR1.4E+06 BIn-house real time PCR2.2E+06 CIn-house qualitative PCR2.5E+05 DIn-house real time PCR2.3E+05 E1. Artus RealArt HBV LC PCR4.2E Bayer VERSANT HBV E+06 FHBV RealType PCR8.4E+05 GIn-house real time PCR2.5E+05 H1. Cobas Amplicor HBV monitor1.3E In-house real time PCR1.9E+06 I1. Cobas Amplicor HBV monitor1.3E Cobas TAQMAN3.2E+06 JArtus RealArt HBV LC PCR8.2E+05 KDigene kit6.6E+05 1 st National HBV DNA Standard

E1C D G JF I1 K A B E2 H1 H2 I2 HBV DNA standard Estimated IU (log 10 /ml) Numbers

+2SD -2SD Average 5.955

1 st National HBV Working Reagent Lab Methodology/kitResult (IU/mL) AIn-house real time PCR2.2E+02 BIn-house real time PCR2.9E+03 CIn-house qualitative PCR2.5E+02 DIn-house real time PCR9.5E+02 E1.Artus RealArt HBV LC PCRND* 2.Bayer VERSANT HBV E+03 FHBV RealType PCR1.4E+03 GIn-house real time PCR4.2E+02 H1.Cobas Amplicor HBV monitor1.8E+03 2.In-house real time PCR4.4E+02 I1.Cobas Amplicor HBV monitor1.4E+03 2.Cobas TAQMAN6.4E+03 JArtus RealArt HBV LC PCR6.4E+02 KDigene kitND* *ND: not detectable

Estimated IU (log10/ml) ACG H2 J D E2 F H1 I1 B I2 Working reagent Numbers

+2SD -2SD Average 2.953

Summary of National HBV DNA Standard and Working Reagent product item 1 st National HBV DNA standard 1 st National HBV working reagent IU/ml Lot Number BFDA lot 92-08BFDA lot 92-08W GenotypeBB Vol. & Amount0.5ml/vial 500 vials 1 ml/vial 1000 vials Storage StateLiquid Frozen

Stability Test – HBV DNA Standard at 5 ±3 o C days

Stability Test – HBV DNA Working Reagent at 5 ±3 o C Cobas Amplicor days

Summary  The assigned potency of HBV DNA standard and HBV working reagent are 10 6 IU/ml and 10 3 IU/ml, respectively.  Genotype of national HBV DNA standard and working reagents is genotype B; and the serotype is adw.  National HBV DNA standard and working reagent are stable at 4 ℃ for 4 weeks.

HBV NAT Experience in Taiwan

Blood center （ Date collected ） Tainan （ March 2003 ） Taipei （ June 2003 ） Taipei （ June 2003 ） Units screened 1440 ＊ 1296 ＊ 516 ＊＊ HBVHBV EIA-positive NAT-negative 000 EIA-negative NAT-positive 006 (1.2 %) EIA-positive NAT-positive 17 （ 1.2 % ） 5 （ 0.4 % ） 2 （ 0.4 % ）（ 1 ） EIA ： Murex HBsAg version 3.0 kit; Sensitivity: <0.2 ng （ 2 ） NAT ＊ Pooled units test (12 units/pool); Roch High Pure Viral Nucleic Acid Kit (0.2 ml of extraction volume); In house nested PCR; Sensitivity of 22 IU/ml. ＊＊ Single unit test Ampliscreen HBV/Roch (1 ml of extraction volume) ; In house nested PCR ； Sensitivity of 12 IU/ml